WuXi Biologics and AI: How Can AI Collaboration Break Through Contract Manufacturing Bottlenecks?

On March 12, WuXi Biologics announced a strategic partnership with AI-driven pharmaceutical company Earendil Labs, providing integrated development and manufacturing services for multiple bispecific/multispecific antibodies and antibody-drug conjugates (ADCs) used to treat autoimmune diseases and tumors.

A Critical Crossroads

This collaboration comes as WuXi Biologics reports its 2025 annual results, amid a recovery in the global biopharmaceutical CRDMO industry and accelerated integration of AI with cutting-edge drugs. The company’s resilience, business structure, technological barriers, and long-term value are attracting market attention.

On one side are impressive financial data and order backlog; on the other are geopolitical tensions, industry competition, and debate over business models. As a leading CXO (Contract Development and Manufacturing Organization), WuXi Biologics stands at a pivotal point of growth and transformation.

In 2025, WuXi Biologics delivered results exceeding market expectations. According to earnings forecasts, the company achieved revenue of 21.79 billion RMB, up 16.7% year-over-year; net profit attributable to shareholders was 4.908 billion RMB, a 46.3% increase; gross margin rose by 5 percentage points to 46%, and adjusted net profit reached 6.586 billion RMB, up 22%.

Source: Company Announcement

The core driver of growth was a breakout in complex molecule business, with bispecific/multispecific antibody revenue contributing nearly 20%, a year-over-year increase of over 120%.

By the end of 2025, WuXi Biologics had a total of 945 projects, including 74 Phase III clinical trials and 25 commercial manufacturing projects.

As of June 2025, North America was the largest revenue source, accounting for 60.5%. Singapore and European manufacturing bases steadily ramped up, further diversifying global operations and reducing dependence on any single market.

Financially, the company’s operating cash flow continued to improve, with a healthy debt ratio. Scale effects and technological premium jointly boosted profitability, helping WuXi Biologics shake off growth pressures from COVID-19 business declines.

Multi-Drive Growth Pattern

WuXi Biologics has completed its transformation from a traditional CDMO to an integrated CRDMO, forming a multi-rotation growth pattern of “bispecifics + ADCs + cell and gene therapy (CGT).” Its partnership with Earendil Labs is a key move in positioning itself within the AI-driven pharmaceutical wave.

Earendil, as an AI-powered biopharmaceutical R&D company, possesses leading protein design and high-throughput screening capabilities. It has previously partnered with Sanofi on projects exceeding $1.8 billion. WuXi Biologics leverages its WuXiBody bispecific platform, WuXiDARx ADC platform, and full-process CMC development capabilities to rapidly advance AI-designed molecules into clinical and commercial production, achieving efficient collaboration of “AI discovery + WuXi manufacturing.”

Industry trends show the global biopharmaceutical CDMO market is expanding, expected to surpass $118.9 billion by 2026. Complex molecules like bispecifics, multispecifics, and ADCs are replacing monoclonal antibodies as the main innovation drivers. Outsourcing penetration continues to rise, and AI + CRDMO is becoming a new industry paradigm.

With the deepening of domestic MAH (Marketing Authorization Holder) systems, accelerated overseas expansion of innovative drugs, and the benefits of Asia-Pacific capacity transfer, leading companies continue to enjoy structural industry dividends.

However, geopolitical and regulatory fluctuations still impact overseas expansion; increased competition from international giants and local firms in complex molecules is leading to price pressures; delays in client pipeline development, over-expansion of capacity, and slower technological iteration could directly affect performance and gross margin stability.

This strategic partnership with Earendil Labs is a crucial step for WuXi Biologics to anchor AI innovation sources and strengthen its advantages in complex molecules, prompting the market to reassess its transition from “water seller” to “technology partner.”

In the short term, the company’s order backlog is ample, capacity release is orderly, and growth is relatively certain. AI collaborations are expected to further enhance project acquisition and technological premium.

Long-term, whether WuXi Biologics can truly shed its OEM label and establish irreplaceable technological barriers depends on platform conversion efficiency, global supply chain stability, and compliance management.

For investors, key indicators to watch include project conversion rate, sustained gross margin, and overseas risk resistance. Maintaining rational judgment amid sector growth and operational risks is essential.

WuXi Biologics’ 2025 results demonstrate its resilience as a leader, but whether AI-driven pharma is a genuine transformation or a capital story, and whether high growth can sustain through cycles, ultimately depends on clinical data, order realization, and market performance.

Note to readers: This article is based on publicly available information or interviews. The author does not guarantee the completeness or accuracy of the information. Under no circumstances does this constitute investment advice. Market risks are inherent; invest cautiously! Reproduction or plagiarism without permission is prohibited.